Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Astellas Pharma Company

4503.T
JP3942400007
856273

Price

1,750.50
Today +/-
-0.09
Today %
-0.88 %
P

Astellas Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Astellas Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Astellas Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Astellas Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Astellas Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Astellas Pharma Stock Price History

DateAstellas Pharma Price
10/11/20241,750.50 undefined
10/10/20241,766.00 undefined
10/9/20241,747.00 undefined
10/8/20241,744.00 undefined
10/7/20241,759.00 undefined
10/4/20241,728.00 undefined
10/3/20241,722.50 undefined
10/2/20241,679.50 undefined
10/1/20241,676.50 undefined
9/30/20241,647.00 undefined
9/27/20241,709.50 undefined
9/26/20241,719.00 undefined
9/25/20241,740.00 undefined
9/24/20241,723.50 undefined
9/20/20241,737.00 undefined
9/19/20241,732.00 undefined
9/18/20241,709.50 undefined
9/17/20241,689.00 undefined

Astellas Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Astellas Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Astellas Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Astellas Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Astellas Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Astellas Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Astellas Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Astellas Pharma’s growth potential.

Astellas Pharma Revenue, EBIT and net profit per share

DateAstellas Pharma RevenueAstellas Pharma EBITAstellas Pharma Net Income
2027e1.96 T undefined477.92 B undefined215.95 B undefined
2026e1.83 T undefined441.88 B undefined149.8 B undefined
2025e1.76 T undefined328.76 B undefined56.96 B undefined
20241.6 T undefined124.61 B undefined17.05 B undefined
20231.52 T undefined231.65 B undefined98.71 B undefined
20221.3 T undefined218.15 B undefined124.09 B undefined
20211.25 T undefined250.93 B undefined120.59 B undefined
20201.3 T undefined267.48 B undefined195.41 B undefined
20191.31 T undefined288.23 B undefined222.27 B undefined
20181.3 T undefined277.69 B undefined164.68 B undefined
20171.31 T undefined273.81 B undefined218.7 B undefined
20161.37 T undefined267.18 B undefined193.69 B undefined
20151.25 T undefined210.64 B undefined135.86 B undefined
20141.14 T undefined187.83 B undefined90.87 B undefined
20131.01 T undefined153.87 B undefined82.85 B undefined
2012969.39 B undefined131.52 B undefined78.23 B undefined
2011953.95 B undefined119.18 B undefined67.65 B undefined
2010974.88 B undefined186.41 B undefined122.26 B undefined
2009965.7 B undefined250.4 B undefined170.99 B undefined
2008972.59 B undefined275.91 B undefined177.44 B undefined
2007920.62 B undefined189.39 B undefined131.29 B undefined
2006879.36 B undefined190.4 B undefined103.57 B undefined
2005447.05 B undefined96.1 B undefined33.67 B undefined

Astellas Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (T)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.370.380.410.450.480.420.430.460.480.510.510.450.880.920.970.970.970.950.971.011.141.251.371.311.31.311.31.251.31.521.61.761.831.96
-4.247.779.794.97-11.342.475.595.115.250.91-12.5596.704.695.64-0.710.95-2.151.623.7413.369.4210.06-4.45-0.860.46-0.42-3.943.7317.165.609.714.247.08
65.1266.5264.3965.1165.1169.6071.0767.2265.0665.2665.8968.1368.6669.0271.2872.6270.3368.9767.1367.7771.0073.2975.5575.5777.3777.6478.7380.3180.4881.0181.76---
0.240.260.270.30.310.290.310.310.310.330.340.30.60.640.690.70.690.660.650.680.810.911.040.991.011.011.0211.041.231.31000
70.3480.4281.9792.5697.1788.3195.8690.1793.65104.94100.3996.1190.4189.39275.91250.4186.41119.18131.52153.87187.83210.64267.18273.81277.69288.23267.48250.93218.15231.65124.61328.76441.88477.92
19.0820.9219.7920.3520.3620.8722.1019.6919.4620.7119.6421.5021.6520.5728.3725.9319.1212.4913.5715.3016.4816.8919.4620.8821.3622.0620.5620.0816.8315.257.7718.6924.0924.34
34.7739.7240.5441.876.0948.0157.1940.3555.1759.7659.9633.67103.57131.29177.44170.99122.2667.6578.2382.8590.87135.86193.69218.7164.68222.27195.41120.59124.0998.7117.0556.96149.8215.95
-14.222.073.27-85.45688.1519.10-29.4436.738.320.34-43.84207.5626.7735.15-3.64-28.50-44.6715.645.919.6849.5042.5712.91-24.7034.97-12.08-38.292.90-20.45-82.73234.18162.9944.16
----------------------------------
----------------------------------
1.621.621.821.81.741.861.831.841.811.721.671.662.822.692.542.42.342.312.312.32.252.212.162.112.031.931.881.861.851.831.8000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Astellas Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Astellas Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (T)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (T)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (T)TOTAL ASSETS (T)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (T)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (T)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (T)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (T)TOTAL CAPITAL (T)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
279.91340.57336.15361.85317240.48280.55325.7339.72333.62345.74429.86623.47507.75542.11513.92537.27176.8299.1312.68395.33396.57360.52340.92331.73311.07324.94326.13318.27376.95335.78
101.3106.55109.73103.68103.1489.0497.75110.21115.93121.52119.69127.87226.67230.51221.42221.96226.44261.12261.8284.14308.41332.92327.6309.82319.51342.63347.04343.18382.46427.97534.99
0000000000000000000062.2666.8330.5124.5421.9322.7226.4619.5440.5637.4941.74
33.434.6434.640.2941.1339.540.8247.0350.0956.5956.7440.4693.8690.9891.44105.43111.05116.88111.82128.18135.23156.91161.69182.54147.63151.51151.02164.08153.07174.39248.74
17.9418.1613.8330.0138.6936.954146.9745.6447.1756.959.28106.3136.74122.31122.32113.7898.35108.36102.1912.0712.7317.2218.8524.8229.2318.0519.662933.1733.49
0.430.50.490.540.50.410.460.530.550.560.580.661.050.970.980.960.990.650.780.830.910.970.90.880.850.860.870.870.921.051.19
88.79109.06115.6128.93176.74185.58182.34188.24197.12190.57174.12134.67206.56194.55179.88181.45184.49190.16199.16218.48191.45202.87200.96191.12181.3173.48268.6264.62269.04286.46293.74
33.3530.0930.9834.0437.0759.5458.0181.8557.9754.3667.6159.47242.16210.69157.7789.5670.860.260.5361.6585.39101.1980.3854.1859.7875.4666.491.791.01101.96116.66
8.7312.1811.0412.3310.765.230.810.720.710.580.51.682.392.2900000011.3926.5135.6332.6836.0334.9146.5745.1940.6732.7927.76
0.010.010.010.020.030.040.040.040.040.030.030.010.030.040.040.030.040.270.220.20.280.30.340.390.420.430.720.650.620.561.45
75.5273.5375.0674.79000000000029.3226.3822.16101.2694.1995.98116.77136.34150.66168.52212.98225.86278.25284.01303.03328.41418.69
51.2764.153.4338.1550.5694.6984.7956.6653.3462.2554.1545.6151.5855.6756.2355.4357.5864.3945.5943.4154.764.8794.97103.49105.6101.0663.0664.0981.8694.4564.19
0.270.30.290.30.310.380.370.370.350.340.320.260.530.50.460.380.380.680.620.620.740.830.90.941.011.041.451.41.411.412.37
0.70.80.790.840.810.790.830.90.90.90.90.911.581.471.441.351.361.341.41.451.651.791.81.811.861.92.322.272.332.463.57
                                                             
55.7255.9955.9956.9573.7480.0798.899.6999.7499.7699.76100.49102.99103103103103103103103103103103103103103103103103103103
69.6569.9269.9270.8887.6694112.72113.62113.67113.68113.68114.41176.81176.82176.82176.82176.82176.82176.82176.82176.82176.82176.9177.09177.22177.3177.51177.83179.47181.28184.07
0.250.290.320.350.350.390.440.470.520.570.620.640.961.010.920.960.90.880.90.920.860.910.971.020.980.990.910.950.940.910.81
000000-29.74-17.59-0.83-4.1-16.56-11.09-4.3815.72-10.86-62.9-82.54-120.59-147.17-80.93149.77179.55134.2699.59128.18149.64109.09166.63246.88340.1532.92
000000012.217.364.7613.8511.644.2538.0927.8510.0214.159.4812.2615.9728.5928.5929.114.6318.29000000
0.380.410.440.480.510.560.620.680.740.780.830.861.281.341.211.191.111.041.041.131.321.391.421.411.41.421.31.41.471.531.63
38.5343.0946.3249.243.432.3632.1739.9354.8241.2337.5731.2362.5173.0270.0589.7784.0288.6108.41102.83187.03226.6181.56182.83140.91185.28171.95124.78130.74140.24185.19
17.0216.5617.0320.1721.624.9623.5225.0323.6128.0723.8122.8751.9567.8358.5352.6964.9474.5282.494.4600000000136.55143.820
42.568.0244.6485.9787.1894.025761.8161.5276.3847.5265.34185.33166.31155.95141.09128.1976.52123.36116.24152.59192.95230.3216.53280.27311.96282.65331.49398.94497.25613.31
7.599.546.6417.931.21.152.491.571.481.891.2400.411.6700000000000032612014075420.39
0000000014.92000000000001.061.341.510.50.440.4318.1116.117.7313.5566.83
0.110.140.110.170.150.130.120.130.160.150.110.120.30.310.280.280.280.240.310.310.340.420.410.40.420.50.80.590.820.871.29
149.49198.88178.93137.589.5540.2426.2124.148.47.346.825.020.5600000000.750.630.7228.3949.4252.88129.27142.1655.01111.46518.49
1.561.241.431.272.022.79.83.644.764.792.422.31.410.580.260042.2530.9334.7200018.5126.435.1824.6718.165.826.0551.35
62.0942.6842.6841.7944.9845.6252.8859.2558.5257.2955.4543.3365.0162.2943.534.6733.0832.137.435.2943.1954.11126.0595.592.4583.5373.35134.82123.84105.02118.05
213.14242.8223.04180.56136.5588.5588.8987.0371.6769.4164.750.6466.9862.8743.7634.6733.0874.3568.347043.9454.74126.77142.41168.3141.59227.29295.14184.68222.53687.89
0.320.380.340.350.290.220.20.220.230.220.170.170.370.370.330.320.310.310.380.380.380.480.540.540.590.641.030.891.011.091.97
0.690.790.780.830.80.780.820.890.96111.031.651.711.541.51.421.361.421.521.711.871.961.951.992.062.322.292.482.633.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Astellas Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Astellas Pharma's financial health and stability.

Assets

Astellas Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Astellas Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Astellas Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Astellas Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
91.35104.7693.0393.22103.2470.62177.07211.76268.78262.69186.8103.48127.07124.67121.98189.68261.77281.77218.11248.97245.35145.32156.89132.36
25.9731.2326.7126.0825.1228.0437.6433.9736.9542.8948.4765.6765.557.8664.365.4769.1963.7964.8663.4666.472.6579.68105.74
000000000000000000000000
-39.69-48.16-26.65-35.03-70.11-29.12-76.54-48.86-95.28-99.47-89.48-71.29-22.98-71.9-22.42-73.78-13.75-105.35-7.91-61.92-102.19-2.21-52.784.5
1.77-16.563.611.52-14.86-17.9368.8-69.62-24.6-8.324.342.773.0833.5350.46.31-3.47-4.637.546.3912.4491.0873.6585.17
1.230.530.820.390.640.81.350.320.05000.22000000000000
39.553.5333.6523.4769.7631.1358.6792.2998.2586.5379.3244.450.2543.4443.1268.2590.417265.0269.9147.9917.8742.0969.48
79.471.2896.785.7943.3851.61206.96127.26185.85197.79150.13100.64172.67144.15214.26187.69313.74235.61312.62256.9222306.84257.44327.77
-35,693-33,924-26,064-23,338-16,403-14,990-24,298-40,736-40,288-47,555-64,299-50,713-64,127-67,545-56,146-81,166-118,117-48,648-40,285-52,128-77,888-77,441-76,448-88,541
-78.0144.55-9.02-3.98-12.8446.96-87.6672.43-8.42-28.99-31.58-242.65-25.95-48.61-26.85-71.48-147.05-73.38-121.8-41.76-389.79-81.89-62.41-84.5
-42.3278.4817.0519.363.5661.95-63.36113.1731.8718.5732.72-191.9338.1718.9329.39.69-28.93-24.74-81.5110.37-311.91-4.4514.044.04
000000000000000000000000
-2.54-1.31-0.86-15.48-1.1-1.2-1.632.08-1.6500-34.9700000000308.34-141.89-77.82-31.5
00-69,689-31,714-39-12,581-46,399-220,046-81,913-123,600-26,996-29-11-49,392-30,075-58,229-120,127-92,193-130,712-160,442-52,899-9,163-50,717-60,556
-10.79-10.38-80.04-57.62-11.22-24.69-76.77-263.52-131.42-184.67-85.9-93.27-57.94-109.73-89.4-121.12-193.48-166.15-203.43-233.68181.06-229.48-216.3-195.62
-267.00-51.00-460.00-926.00-141.00-698.00-6,560.00-1,484.00-1,975.00-2,450.00-2,503.00-542.00-198.00-284.00-664.00-743.00-3,736.00-3,841.00-1,083.00-1,173.00-847.00-2,268.00-2,530.00-3,217.00
-7,982-9,011-9,028-9,499-9,932-10,210-22,181-44,066-45,878-58,624-56,401-57,727-57,729-60,050-58,656-62,146-69,615-70,119-71,634-72,066-73,539-76,157-85,236-100,355
-20.16109.6315.9122.5914.3577.9849.94-50.9137.97-50.6622.1-256.4576.9112.53126.465.06-36.4-19.11-9.19-20.667.327.74-10.1460.85
43,70337,35570,64062,45026,97336,619182,66686,520145,557150,23785,82949,925108,54776,606158,111106,519195,619186,964272,330204,771144,109229,402180,995239,226
000000000000000000000000

Astellas Pharma stock margins

The Astellas Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Astellas Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Astellas Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Astellas Pharma's sales revenue. A higher gross margin percentage indicates that the Astellas Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Astellas Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Astellas Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Astellas Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Astellas Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Astellas Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Astellas Pharma Margin History

Astellas Pharma Gross marginAstellas Pharma Profit marginAstellas Pharma EBIT marginAstellas Pharma Profit margin
2027e81.76 %24.34 %11 %
2026e81.76 %24.09 %8.17 %
2025e81.76 %18.69 %3.24 %
202481.76 %7.77 %1.06 %
202381.01 %15.25 %6.5 %
202280.48 %16.83 %9.57 %
202180.31 %20.08 %9.65 %
202078.73 %20.56 %15.02 %
201977.64 %22.06 %17.01 %
201877.37 %21.36 %12.66 %
201775.57 %20.88 %16.67 %
201675.55 %19.46 %14.11 %
201573.29 %16.89 %10.89 %
201471 %16.48 %7.97 %
201367.77 %15.3 %8.24 %
201267.13 %13.57 %8.07 %
201168.97 %12.49 %7.09 %
201070.33 %19.12 %12.54 %
200972.62 %25.93 %17.71 %
200871.28 %28.37 %18.24 %
200769.02 %20.57 %14.26 %
200668.66 %21.65 %11.78 %
200568.13 %21.5 %7.53 %

Astellas Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Astellas Pharma earnings per share therefore indicates how much revenue Astellas Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Astellas Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Astellas Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Astellas Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Astellas Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Astellas Pharma Revenue, EBIT and net profit per share

DateAstellas Pharma Sales per ShareAstellas Pharma EBIT per shareAstellas Pharma Earnings per Share
2027e1,097.18 undefined0 undefined120.65 undefined
2026e1,024.67 undefined0 undefined83.69 undefined
2025e982.96 undefined0 undefined31.82 undefined
2024891.1 undefined69.24 undefined9.47 undefined
2023832.09 undefined126.93 undefined54.09 undefined
2022700.4 undefined117.88 undefined67.05 undefined
2021672.83 undefined135.12 undefined64.93 undefined
2020692.84 undefined142.46 undefined104.08 undefined
2019675.55 undefined149.05 undefined114.94 undefined
2018639.77 undefined136.63 undefined81.02 undefined
2017621.06 undefined129.65 undefined103.55 undefined
2016635.13 undefined123.62 undefined89.62 undefined
2015563.74 undefined95.2 undefined61.4 undefined
2014506.63 undefined83.48 undefined40.39 undefined
2013437.22 undefined66.9 undefined36.02 undefined
2012419.29 undefined56.89 undefined33.84 undefined
2011412.61 undefined51.55 undefined29.26 undefined
2010417.15 undefined79.77 undefined52.31 undefined
2009402.04 undefined104.25 undefined71.18 undefined
2008383.36 undefined108.75 undefined69.94 undefined
2007342.24 undefined70.41 undefined48.8 undefined
2006311.72 undefined67.49 undefined36.71 undefined
2005269.8 undefined58 undefined20.32 undefined

Astellas Pharma business model

Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.com.

Astellas Pharma SWOT Analysis

Strengths

Astellas Pharma Inc has built a strong brand reputation in the pharmaceutical industry through its high-quality products, ethical business practices, and commitment to innovation.

The company offers a diverse range of pharmaceutical products across multiple therapeutic areas, providing a competitive advantage and reducing dependence on a single product or market.

Astellas Pharma Inc has a global presence with operations in multiple countries, allowing the company to capitalize on international market opportunities and reach a larger customer base.

The company invests significantly in research and development, fostering innovation and enabling the development of novel drugs and treatments that address unmet medical needs.

Weaknesses

Astellas Pharma Inc relies heavily on a few key products for a significant portion of its revenue, making the company vulnerable to potential declines in sales if these products face competition or patent expiration.

The pharmaceutical industry is subject to strict regulations and compliance requirements, and changes in regulations or unexpected challenges in obtaining regulatory approvals can impact the company's product pipeline and business operations.

Opportunities

Astellas Pharma Inc can expand its market presence by targeting emerging markets, where growing populations, increasing healthcare spending, and rising awareness of healthcare contribute to significant growth opportunities.

The company can explore opportunities in the field of biotechnology, which offers potential for the development of innovative therapies and treatments that align with changing medical needs and technological advancements.

Threats

Astellas Pharma Inc operates in a highly competitive industry, facing competition from other pharmaceutical companies, generic drug manufacturers, and new entrants, which can impact market share and pricing.

The company's intellectual property rights may be challenged or infringed upon by competitors, affecting market exclusivity and potentially leading to revenue loss.

Government interventions such as price controls and healthcare reforms can impact the pricing and reimbursement of pharmaceutical products, posing financial challenges and potentially affecting profitability for Astellas Pharma Inc.

Astellas Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Astellas Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Astellas Pharma shares outstanding

The number of shares was Astellas Pharma in 2023 — This indicates how many shares 1.825 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Astellas Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Astellas Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Astellas Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Astellas Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Astellas Pharma stock splits

In Astellas Pharma's history, there have been no stock splits.

Astellas Pharma dividend history and estimates

In 2023, Astellas Pharma paid a dividend amounting to 65 JPY. Dividend means that Astellas Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Astellas Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Astellas Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Astellas Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Astellas Pharma Dividend History

DateAstellas Pharma Dividend
2027e73.74 undefined
2026e73.85 undefined
2025e73.66 undefined
202472 undefined
202365 undefined
202255 undefined
202146 undefined
202041 undefined
201939 undefined
201837 undefined
201735 undefined
201633 undefined
201532 undefined
201428 undefined
201326 undefined
201226 undefined
201125 undefined
201025 undefined
200924 undefined
200824 undefined
200718 undefined
200616 undefined
20059.2 undefined

Astellas Pharma dividend payout ratio

In 2023, Astellas Pharma had a payout ratio of 64.09%. The payout ratio indicates the percentage of the company's profits that Astellas Pharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Astellas Pharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Astellas Pharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Astellas Pharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Astellas Pharma Payout Ratio History

DateAstellas Pharma Payout ratio
2027e71.62 %
2026e69.74 %
2025e72.81 %
202472.32 %
202364.09 %
202282.03 %
202170.84 %
202039.39 %
201933.93 %
201845.67 %
201733.8 %
201636.82 %
201552.11 %
201469.32 %
201372.16 %
201276.85 %
201185.44 %
201047.78 %
200933.72 %
200834.32 %
200736.89 %
200643.58 %
200545.23 %
Unfortunately, there are currently no price targets and forecasts available for Astellas Pharma.

Astellas Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202412.45 21  (68.68 %)2025 Q1
3/31/20244.66 -18.55  (-497.88 %)2024 Q4
12/31/202315.46 10.4  (-32.71 %)2024 Q3
9/30/202325.83 -0.81  (-103.15 %)2024 Q2
6/30/202331.73 18.46  (-41.82 %)2024 Q1
3/31/2023-10.52 -25.49  (-142.19 %)2023 Q4
12/31/202239.63 26.56  (-32.98 %)2023 Q3
9/30/202233.94 39.28  (15.72 %)2023 Q2
6/30/202223.52 13.6  (-42.19 %)2023 Q1
3/31/202224.44 -4.43  (-118.12 %)2022 Q4
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Astellas Pharma stock

Eulerpool World ESG Rating (EESG©)

91/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

76

Environment

Scope 1 - Direct Emissions
63,691
Scope 2 - Indirect emissions from purchased energy
54,988
Scope 3 - Indirect emissions within the value chain
200,016
Total CO₂ emissions
118,679
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees46.9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Astellas Pharma shareholders

%
Name
Stocks
Change
Date
5.79102 % Nomura Asset Management Co., Ltd.103,650,910-190,3003/31/2024
3.13618 % The Vanguard Group, Inc.56,133,2111,171,1003/31/2024
2.88224 % Nippon Life Insurance Company51,588,00009/30/2023
2.85612 % Mitsubishi UFJ Trust and Banking Corporation51,120,500-6,301,50010/9/2023
2.76937 % Nikko Asset Management Co., Ltd.49,567,74866,5003/31/2024
2.75551 % Daiwa Asset Management Co., Ltd.49,319,719-145,8193/31/2024
2.50560 % BlackRock Japan Co., Ltd.44,846,70035,550,7007/31/2023
1.96823 % BlackRock Fund Advisors35,228,41535,177,0157/31/2023
1.91406 % JPMorgan Securities Japan Co., Ltd.34,259,00015,046,0009/30/2023
1.73450 % BlackRock Institutional Trust Company, N.A.31,045,089-16,519,5777/31/2023
1
2
3
4
5
...
10

Astellas Pharma Executives and Management Board

Mr. Kenji Yasukawa63
Astellas Pharma Chairman of the Board, Chairman of the Board of Directors, Representative Director
Compensation 452 M
Mr. Naoki Okamura60
Astellas Pharma President, Chief Executive Officer, Representative Director (since 2016)
Compensation 204 M
Mr. Katsuyoshi Sugita55
Astellas Pharma Vice President, Chief People Officer, Chief Ethics & Compliance Officer, Representative Director (since 2022)
Mr. Hideki Shima
Astellas Pharma Senior Managing Executive Officer
Mr. Yoshitsugu Shitaka
Astellas Pharma Senior Managing Executive Officer (since 2023)
1
2
3
4

Astellas Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
BANDAI NAMCO Holdings Stock
BANDAI NAMCO Holdings
SupplierCustomer0,820,450,29-0,150,220,14
Modalis Therapeutics Stock
Modalis Therapeutics
SupplierCustomer0,74-0,130,19-0,61-0,24-
CAC Stock
CAC
SupplierCustomer0,74-0,010,08-0,52-0,160,21
Sanofi Stock
Sanofi
SupplierCustomer0,720,760,740,750,500,62
ON24 Stock
ON24
SupplierCustomer0,690,68--0,49-0,12-
Teva Pharmaceutical Inds Stock
Teva Pharmaceutical Inds
SupplierCustomer0,660,800,460,310,02-0,38
Avalo Therapeutics Stock
Avalo Therapeutics
SupplierCustomer0,640,77-0,37-0,68-0,33-0,44
JMDC Stock
JMDC
SupplierCustomer0,620,680,35-0,39-0,110,44
SymBio Pharmaceuticals Stock
SymBio Pharmaceuticals
SupplierCustomer0,610,07-0,27-0,49-0,140,48
Kyowa Kirin Stock
Kyowa Kirin
SupplierCustomer0,600,05-0,03-0,52-0,180,43
1
2
3
4
5
...
6

Most common questions regarding Astellas Pharma

What values and corporate philosophy does Astellas Pharma represent?

Astellas Pharma Inc represents values of integrity, dedication, and innovation. With a strong corporate philosophy centered around "Contributing toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products," Astellas Pharma Inc emphasizes the importance of patient well-being and healthcare advancement. Through their research and development efforts, they strive to introduce cutting-edge therapies and medicines to meet unmet medical needs. With an unwavering commitment to ethical conduct and a focus on creating sustainable value, Astellas Pharma Inc demonstrates its dedication to improving global health outcomes.

In which countries and regions is Astellas Pharma primarily present?

Astellas Pharma Inc is primarily present in various countries and regions worldwide. The company has an extensive global presence, with operations spanning across North America, Europe, Asia, and numerous other regions. Astellas Pharma Inc is actively engaged in pharmaceutical research, development, and commercialization in countries such as the United States, Japan, Europe (including the United Kingdom and Germany), China, and many more. With its commitment to improving the health and well-being of people globally, Astellas Pharma Inc has established a significant presence in key markets around the world.

What significant milestones has the company Astellas Pharma achieved?

Astellas Pharma Inc, a renowned pharmaceutical company, has achieved several significant milestones throughout its history. One notable accomplishment is the discovery and development of innovative drugs that have improved the treatment options for various medical conditions. The company has also excelled in creating strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies to foster research collaboration and enhance its product pipeline. Additionally, Astellas Pharma Inc has successfully expanded its global presence by entering new markets and establishing strong footholds in key regions worldwide. These accomplishments demonstrate Astellas Pharma Inc's commitment to advancing healthcare through groundbreaking research, development, and strategic growth initiatives.

What is the history and background of the company Astellas Pharma?

Astellas Pharma Inc. is a leading pharmaceutical company founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Based in Tokyo, Japan, Astellas specializes in the research, development, and commercialization of innovative drugs and medical solutions. With a strong focus on areas such as urology, immunology, and oncology, Astellas has established itself as a global player in the healthcare industry. The company continually strives to improve patient lives through its cutting-edge products and dedication to scientific advancements. Astellas Pharma Inc. remains committed to addressing unmet medical needs and contributing to the overall well-being of communities worldwide.

Who are the main competitors of Astellas Pharma in the market?

The main competitors of Astellas Pharma Inc in the market include Pfizer, Johnson & Johnson, Novartis, GlaxoSmithKline, and Merck & Co.

In which industries is Astellas Pharma primarily active?

Astellas Pharma Inc is primarily active in the pharmaceutical industry. The company specializes in the research, development, manufacturing, and sale of innovative pharmaceutical products. With a focus on therapeutic areas such as oncology, urology, immunology, and infectious diseases, Astellas Pharma Inc aims to improve patients' lives through the discovery of innovative and effective treatments. As a renowned global pharmaceutical company, Astellas Pharma Inc actively collaborates with healthcare professionals, organizations, and academic institutions to advance medical knowledge and provide quality healthcare solutions worldwide.

What is the business model of Astellas Pharma?

The business model of Astellas Pharma Inc, a leading pharmaceutical company, focuses on research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas Pharma Inc specializes in therapeutic areas such as urology, immunology, nephrology, and oncology. With a patient-centric approach, Astellas strives to improve the health and well-being of people worldwide by delivering breakthrough treatments. They collaborate with healthcare professionals, organizations, and researchers to drive scientific advancements and enhance patient outcomes. Astellas Pharma Inc's dedication to innovation, strategic partnerships, and global expansion sets it apart in the pharmaceutical industry, allowing them to continue making a positive impact on the lives of patients.

What is the P/E ratio of Astellas Pharma 2024?

The Astellas Pharma P/E ratio is 184.82.

What is the P/S ratio of Astellas Pharma 2024?

The Astellas Pharma P/S ratio is 1.96.

What is the Quality Investing of Astellas Pharma?

The Quality Investing for Astellas Pharma is 3/10.

What is the revenue of Astellas Pharma 2024?

The Astellas Pharma revenue is 1.6 T JPY.

How high is the profit of Astellas Pharma 2024?

The Astellas Pharma profit is 17.05 B JPY.

What is the business model of Astellas Pharma

Astellas Pharma Inc. is a Japanese pharmaceutical company specializing in the development and marketing of innovative therapies for various diseases. The company is divided into three main areas: Pharmaceuticals, OTC products (Non-Prescription products), and Diagnostics.

What is the Astellas Pharma dividend?

Astellas Pharma pays a dividend of 55 JPY distributed over 2 payouts per year.

How often does Astellas Pharma pay dividends?

Astellas Pharma pays out a dividend 2 times a year.

What is the Astellas Pharma ISIN?

The ISIN of Astellas Pharma is JP3942400007.

What is the Astellas Pharma WKN?

The WKN of Astellas Pharma is 856273.

What is the Astellas Pharma ticker?

The ticker of Astellas Pharma is 4503.T.

How much dividend does Astellas Pharma pay?

Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.11 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.

What is the dividend yield of Astellas Pharma?

The current dividend yield of Astellas Pharma is 4.11 %.

When does Astellas Pharma pay dividends?

Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Astellas Pharma?

Astellas Pharma paid dividends every year for the past 23 years.

What is the dividend of Astellas Pharma?

For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.21 %.

In which sector is Astellas Pharma located?

Astellas Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astellas Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Astellas Pharma pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Astellas Pharma in the year 2023?

In the year 2023, Astellas Pharma distributed 65 JPY as dividends.

In which currency does Astellas Pharma pay out the dividend?

The dividends of Astellas Pharma are distributed in JPY.

All fundamentals about Astellas Pharma

Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.